In related to the increased risk of cardio vascular (CV) diseases associated with migraine, there is a interest in the development of a new drug in the treatment of acute migraine which selectively act on non-vascular targets. Existing treatments are limited due to contra indications, or patient avoidance of side effects. This analysis show that 5-HT1F agonist have shown improved results in the treatment of migraine head ache. Also indicated the safety and efficacy of oral lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist in the migraine treatment. Research suggests that lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment in patient’s refractory to the acute migraine medications compared to the currently used drugs for migraine.
Ardra PK, Kavya Prathap, Sherin M Saji, Irene Thomas, Ansa Mathew. Lasmiditan: A new drug for acute migraine. International Journal of Pharmacology and Pharmaceutical Sciences, Volume 1, Issue 1, 2019, Pages 17-19